Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce cisplatin-induced hearing loss in pediatric cancer patients. The company also monetizes its asset through licensing arrangements, including commercialization rights outside the U.S. for PEDMARQSI®/PEDMARK®.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSales of PEDMARK® in the U.S. and related branded product commercialization.
Out-licensing of PEDMARQSI® rights to partners for Europe, Australia and New Zealand.
Non-refundable upfront payments and milestone receipts under collaboration agreements.
Asiakkaat
Fennec sells primarily into the life sciences and pharmaceutical ecosystem rather than to mass-market consumers. Its direct customers include hospitals, oncology treatment centers, and pharmaceutical partners that commercialize or license PEDMARK/PEDMARQSI in specific territories.
Hospitals and cancer centers buy PEDMARK for children receiving cisplatin to reduce hearing-loss risk.
Partners license rights to market PEDMARQSI/PEDMARK in defined territories and pay milestones or royalties.
Channel partners distribute the product to treatment sites and support access and reimbursement.
Ex-U.S. markets buy through local commercialization partners as approvals and launches expand.
Strategia
Fennec is pursuing commercialization of its single approved product while broadening access through regional licensing partnerships. Management is also actively evaluating strategic alternatives and collaborations to secure funding, extend runway, and support future development and commercialization efforts.
The company depends heavily on one commercial asset, so uptake drives revenue and operating leverage.
Licensing reduces direct operating burden while expanding market reach and potential royalty streams.
Working capital needs remain uncertain and the company references further capital requirements.
Maantiede
The company is headquartered in the United States, where PEDMARK was first approved and where commercial activity is centered. Outside the U.S., Fennec has expanded through licensing, with PEDMARQSI approved in the EU and U.K. and launched in Germany and the U.K. through Norgine. This makes the business dependent on regulatory approvals and partner execution in Europe and other ex-U.S. markets.
Riskit
Fennec is highly concentrated in a single product and therefore exposed to adoption, reimbursement, and regulatory execution risk. Its partner-led international expansion reduces direct investment needs but increases dependence on third parties, while ongoing capital needs and clinical/regulatory uncertainty remain material for a small biopharma company.
Revenue and strategic value are tied primarily to PEDMARK/PEDMARQSI, so any setback would materially affect the business.
Kohdistuu: PEDMARK commercialization
International growth relies on Norgine and other collaborators to launch, market, and distribute the product.
Management states future capital requirements are uncertain and may depend on collaboration proceeds or financing.
Kohdistuu: Working capital and runway
Approvals, label scope, and reimbursement determine whether hospitals can adopt the therapy at scale.
Kirjanpito
Harkinnanvaraiset erätUpfront fees, milestones, and royalties require allocation and judgment on when obligations are satisfied.
Vaikutus: Can shift revenue between periods and affect comparability.
Receivables are evaluated using customer history, macro factors, and industry conditions.
Vaikutus: Affects bad debt expense and net receivables.
PSU vesting depends on revenue milestones and is expensed when probable.
Vaikutus: Can increase compensation expense if milestones are expected to be achieved.
Money market balances are exposed to fair value and liquidity considerations.
Vaikutus: Minor but relevant for treasury and liquidity analysis.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Medicus Pharma Ltd.
MDCXW · Pharmaceutical Preparations
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
Päivitetty: 24.9.2026